subscribeSubscribe
price-trendAsk Us
FDA Confirms Paragraph IV Patent Litigation for Raltegravir Potassium Tablets

FDA Confirms Paragraph IV Patent Litigation for Raltegravir Potassium Tablets

FDA
14 Dec 2022
Share Share
Roche, Merck, Novartis and others hike prices on 83 meds starting in July

Roche, Merck, Novartis and others hike prices on 83 meds starting in July
Eric Sagonowsky FIERCE PHARMA
10 Jul 2019
Share Share
US FDA approves Merck`s once-daily dose of Isentress in combo

US FDA approves Merck`s once-daily dose of Isentress in combo
PHARMABIZ
30 May 2017
Share Share
Merck shops for hefty M&A amid `uninspiring` Q1 for new meds

Merck shops for hefty M&A amid `uninspiring` Q1 for new meds
Tracy Staton FIERCE PHARMA
05 May 2016
Share Share
Merck’s phase 3 study of once-daily Isentress in HIV-1 adults meet endpoints

Merck’s phase 3 study of once-daily Isentress in HIV-1 adults meet endpoints
PHARMABIZ
23 Feb 2016
Share Share
GSK`s HIV bright spot could get brighter with new Tivicay combo meds

GSK`s HIV bright spot could get brighter with new Tivicay combo meds
Tracy Staton FIERCE PHARMA MARKETING
04 Nov 2015
Share Share
Merck Grants Free License For Pediatric HIV Drug

Merck Grants Free License For Pediatric HIV Drug
Linda A. Johnson PHILLY.COM
25 Feb 2015
Share Share
Merck Sharp Dohme`s Dutrebis (Lamivudine 150Mg /Raltegravir 300Mg) Approved in USA for HIV-1 Infection

Merck Sharp Dohme`s Dutrebis (Lamivudine 150Mg /Raltegravir 300Mg) Approved in USA for HIV-1 Infection
Press Release FDA
06 Feb 2015
Share Share